Eperistad is a muscle relaxant. Eperisone hydrochloride exhibits both skeletal muscle relaxant and vasodilator properties due to its actions within the central nervous system (CNS) and on vascular smooth muscle. Eperisone hydrochloride has an established therapeutic value in improving various symptoms associated with myotonia, improving circulation.

Pack size Box of 30 tablets, 50 tablets
Shelf-life 24 months
Composition Eperisone hydrochloride
Dosage forms and strengths Film-coated tablet: 50 mg
Product code :



  • Improvement of myotonic symptoms associated with the following diseases: Cervical syndrome, periarthritis of the shoulder, and lumbago.
  • Spastic paralysis associated with the following diseases: Cerebrovascular diseases, spastic spinal paralysis, cervical spondylosis, postoperative sequelae (including cerebrospinal tumor), sequelae to trauma (spinal trauma, head injury), amyotrophic lateral sclerosis, cerebral palsy, spinocerebellar degeneration, spinal vascular diseases, and other encephalomy elopathies.


  • Usually for adults
    50 mg three times daily after meals. The dosage should be adjusted according to the patient age and severity of symptoms.
  • Peadiatric
    Safety in children has not been established (adequate clinical studies in children have not been performed).


  • Administered orally.

Patients with history of hypersensitivity to eperisone hydrochloride or to any of the excipients.

  • Rash, psychoneurologic symptoms such as insomnia, headache, drowsiness, numbress in the extremities or stiffness or trembling in the extremities.
  • Digestive symptoms such as nausea, vomiting, anorexia, dry mouth, constipation, diarrhea, abdominal pain or other gastrointestinal disorders symptoms; symptoms of urinary disorders.
  • Weakness, lightheadedness or drowsiness may occur with the use of this drug. Discontinue use or decrease dosage at the first sign of such symptoms.
  • Patients with hepatic disorders should be careful when taking drug.
  • This drug should be administered to pregnant patients or women suspected of being pregnant, only if the expected therapeutic benefit is thought to outweigh any possible risk.
  • Eperisone hydrochloride is not recommended for woman during lactation. If use during lactation is necessary, the patient should discontinue breast feeding.
  • Patients taking this drug should not driving a vehicle or operating hazardous machinery.